A common practitioner mistake: treating osteoporosis based entirely on DEXA scan results, then waiting two to five years to find out whether the intervention worked. By then, significant additional bone loss may have already occurred. The Kharrazian Institute's clinical training addresses this gap directly, teaching practitioners how to use urinary bone resorption markers to monitor active bone breakdown in real time — closing the window between intervention and confirmation of response.
Dr. Kharrazian's clinical teaching emphasizes that bone health requires both structural and biochemical assessment. DEXA quantifies what has already been lost. Resorption markers tell you what is being lost right now.
What DEXA Scans Can and Cannot Tell You
DEXA scans remain the clinical standard for diagnosing osteopenia and osteoporosis. They provide a reliable snapshot of bone mineral density at a given point in time. The limitation is built into the methodology: bone density changes slowly enough that meaningful structural differences between two scans typically require a two-to-five-year interval. A patient can lose significant bone mass in the interim, and the practitioner has no signal until the next imaging cycle.
Bone loss is often asymptomatic until fracture. The first clinical indicator for many patients is the fracture itself. Waiting for structural change to appear on imaging is, in that sense, waiting for the outcome you were trying to prevent.
DEXA also does not reveal why bone density is declining. A low T-score tells you the result, not the mechanism. Whether the driver is estrogen insufficiency, vitamin D metabolic dysfunction, elevated cortisol, calcium malabsorption, or accelerated osteoclast activity, the scan reads the same. Intervening without identifying the mechanism is working without a target.
How Urinary Bone Resorption Markers Work
When bone is broken down by osteoclasts, the process releases breakdown products of type I collagen into circulation. These fragments are filtered and excreted in urine, where they can be measured directly. The primary markers used clinically are:
- CTX (C-terminal telopeptide of type I collagen) — highly sensitive to acute changes in bone resorption activity; often the first to respond to intervention
- NTX (N-terminal telopeptide of type I collagen) — reflects ongoing collagen degradation; useful for tracking trends over time
- PYD (pyridinoline) — a collagen crosslink released during bone matrix breakdown
- DPD (deoxypyridinoline) — bone-specific crosslink; less influenced by soft tissue collagen turnover than PYD
Elevated levels of these markers indicate that bone resorption is outpacing formation. The clinical value is speed: resorption markers respond to metabolic interventions in weeks, not years. A practitioner can implement a protocol, retest in six to eight weeks, and determine whether bone breakdown has slowed before committing to long-term pharmacological management or continuing a non-pharmacological approach.
What Drives Elevated Bone Resorption Markers?
Elevated resorption markers are not a diagnosis. They are a signal that bone catabolism is accelerated, and the clinical task is to identify why.
Research in endocrinology and bone metabolism identifies several well-established drivers. Estrogen decline is among the most significant — estrogen directly suppresses osteoclast activity, and its reduction accelerates resorption. Testosterone insufficiency in men produces a parallel effect. Elevated cortisol, whether from chronic physiological stress or exogenous corticosteroid use, increases bone turnover and reduces osteoblast function simultaneously.
Vitamin D insufficiency disrupts calcium homeostasis and impairs the mineralization necessary for new bone formation, but the metabolic picture is more nuanced than a low 25-OH-D level suggests. Vitamin D must be converted to its active form, 1,25-dihydroxyvitamin D3, through a two-step hydroxylation process involving the liver and kidney. Impaired liver function, intestinal permeability, or chronic inflammation can disrupt conversion efficiency even when serum 25-OH-D appears adequate. Dr. Kharrazian's coursework on bone health addresses this distinction specifically, teaching practitioners to evaluate vitamin D metabolism rather than serum levels in isolation.
Parathyroid hormone (PTH) dysregulation is another layer. Chronically elevated PTH, driven by low calcium availability or vitamin D insufficiency, shifts the balance toward resorption. Micronutrient deficiencies in magnesium, vitamin K2, zinc, and boron also impair bone matrix quality and mineralization in ways that DEXA cannot detect.
Intestinal malabsorption is frequently overlooked in bone health evaluation. A patient with compromised absorptive surface area — from atrophic gastritis, intestinal permeability, or a history of gastrointestinal surgery — may have adequate dietary calcium intake and still be calcium-deficient at the tissue level. If that deficiency is driving PTH-mediated resorption, treating with bisphosphonates addresses the symptom, not the mechanism.
Implementing Urinary Bone Markers in Clinical Practice
The practical application is straightforward. Establish baseline resorption marker levels at the time of initial bone health assessment. This gives you a metabolic picture that the DEXA cannot provide: how actively is bone currently being broken down?
If markers are elevated, pursue the underlying mechanism before defaulting to pharmacological intervention. Evaluate hormonal status, vitamin D metabolic pathway, PTH, parathyroid function, digestive competency, and relevant micronutrients. The intervention should match the identified driver.
After implementing a targeted protocol, retest resorption markers at six to eight weeks. A meaningful reduction in CTX or NTX indicates that the metabolic driver has been addressed and bone breakdown is slowing. No change, or continued elevation, indicates the intervention missed the primary mechanism or that an additional factor requires investigation.
This cycle replaces the two-to-five-year wait inherent in sequential DEXA imaging with an iterative, responsive monitoring process. Practitioners can course-correct in months rather than years. For patients with active bone loss, that difference is clinically significant.
Resorption markers are also useful for monitoring compliance and physiological response in patients already on bisphosphonate therapy. Bisphosphonates suppress osteoclast activity, and persistently elevated markers in a patient reporting medication compliance indicate either poor absorption, inadequate dosing, or an underlying driver strong enough to sustain resorption despite pharmacological suppression.
Building a Complete Bone Health Assessment
Structural assessment and biochemical monitoring serve different clinical functions. Neither replaces the other.
DEXA remains the appropriate tool for establishing baseline bone density, diagnosing osteopenia or osteoporosis, and tracking structural outcomes over longer intervals. Urinary resorption markers provide the metabolic signal DEXA cannot: the rate and direction of bone change right now, and the response to intervention in real time.
A complete bone health assessment, as taught in Dr. Kharrazian's clinical coursework, includes bone density imaging, baseline and follow-up resorption markers, hormonal evaluation, vitamin D metabolic assessment, PTH, relevant micronutrient status, and a clinical history that includes digestive function, medication history, and lifestyle factors known to influence bone turnover. This is not a longer list for its own sake. Each element targets a specific mechanism that, if unaddressed, can sustain bone loss regardless of what else is done.
The goal is not to add tests. The goal is to stop treating a structural endpoint without understanding the metabolic process producing it.
Key Takeaways
- DEXA scans measure bone density at a single point in time. Urinary bone resorption markers measure the rate of active bone breakdown, providing metabolic data DEXA cannot.
- CTX, NTX, PYD, and DPD are the primary urinary markers of bone collagen degradation. Elevated levels indicate accelerated osteoclast activity.
- Resorption markers respond to targeted interventions in six to eight weeks, replacing the two-to-five-year gap between sequential DEXA scans with a responsive monitoring cycle.
- Elevated markers require investigation of the mechanism: hormonal status, vitamin D metabolic pathway, PTH, digestive absorption, and micronutrient status all contribute to bone resorption rates.
- Pharmacological intervention without identifying the underlying driver addresses the endpoint, not the cause.
Frequently Asked Questions
Urinary bone resorption markers — CTX, NTX, PYD, and DPD — are breakdown products of type I collagen released during bone matrix degradation. They indicate how actively bone is being broken down at the time of testing, providing metabolic data that bone density imaging cannot capture.
Baseline testing should occur at initial assessment. After implementing a targeted intervention, retesting at six to eight weeks provides clinically meaningful data on treatment response. Ongoing monitoring frequency depends on the clinical picture and whether markers have normalized.
No. They serve different functions. DEXA assesses structural bone density and is necessary for diagnosis of osteopenia and osteoporosis. Resorption markers assess the metabolic rate of bone breakdown. Both are necessary for complete bone health evaluation.
Estrogen or testosterone insufficiency, elevated cortisol, vitamin D metabolic dysfunction, hyperparathyroidism, calcium malabsorption from intestinal dysfunction, and micronutrient deficiencies in magnesium, vitamin K2, zinc, and boron are among the most frequently identified drivers in functional medicine evaluation.
Vitamin D regulates calcium absorption and PTH activity. Insufficient vitamin D raises PTH, which stimulates osteoclast activity and accelerates resorption. Importantly, the metabolic conversion of vitamin D to its active form can be impaired even when serum 25-OH-D levels appear adequate, making metabolic assessment more informative than a single serum level.
About the Author
Dr. Datis Kharrazian, PhD, DHSc, DC, MS, MMSc, FACN is a Harvard Medical School research fellow and researcher at Massachusetts General Hospital's Department of Neurology, specializing in autoimmunity and neuroimmunology. He serves as Associate Clinical Professor at Loma Linda University School of Medicine and is the author of Why Do I Still Have Thyroid Symptoms When My Lab Tests Are Normal and Why Isn't My Brain Working. He holds fellowships from the American College of Nutrition and the Royal Society of Medicine (UK), and is a Diplomate of the Board of Nutrition Specialists and a member of the American Association of Immunologists. The Kharrazian Institute provides clinical education to more than 5,000 physicians and healthcare providers worldwide.
The Kharrazian Institute's bone health coursework provides practitioners with clinical strategies for implementing urinary bone resorption marker monitoring alongside comprehensive metabolic assessment. For information on available courses and clinical training programs, visit the Kharrazian Institute course catalog.
